Clinical Scorecard: Evaluating the Effectiveness of the Active Melioidosis Detect Plus Rapid Test for Identifying Burkholderia pseudomallei in Throat Swab Samples
At a Glance
Category
Detail
Condition
Melioidosis
Key Mechanisms
The Active Melioidosis Detect Plus rapid diagnostic test (AMD-RDT) is a qualitative, membrane-based lateral flow immunoassay targeting Burkholderia pseudomallei capsular polysaccharide.
Target Population
Patients with suspected melioidosis who underwent throat swab collection in Cambodia and Laos.
Care Setting
Two accredited microbiology laboratories providing routine diagnostic services in Southeast Asia.
Key Highlights
AMD-RDT sensitivity was 18.4% (95% CI, 9.2%–33.4%), and specificity was 100% (95% CI, 95.2%–100%).
Positive AMD-RDT results occurred only in specimens positive on direct culture and were associated with greater bacterial burden and culture positivity within 48 hours.
Researchers tested 38 culture-positive specimens and 76 culture-negative controls.
The throat swab was the sole culture-positive specimen in 20 of 38 cases (52.6%).
Culture identified B. pseudomallei in 38 of 1451 throat swab specimens (2.6%); 9 of the 38 positive specimens required enrichment culture for detection.
Guideline-Based Recommendations
The source is a diagnostic accuracy study rather than a clinical guideline. The following points reflect its findings and discussion.
Diagnosis
Culture remains the diagnostic gold standard for melioidosis.
The authors do not recommend routine AMD-RDT use on throat swabs because sensitivity is inadequate.
A negative throat swab AMD-RDT result cannot reliably exclude melioidosis.
Management
The study does not evaluate treatment strategies. AMD-RDT results were not reported to clinical teams or used to guide patient management.
Monitoring & Follow-up
The study does not provide recommendations for clinical monitoring or follow-up.
Risks
Diagnostic delays contribute to high mortality because B. pseudomallei is intrinsically resistant to many first-line antimicrobials.
Broader-spectrum empirical therapy may promote antimicrobial resistance.
Patient & Prescribing Data
Between July 11, 2023, and December 31, 2024, the laboratories received 1451 throat swab specimens from 1375 patients with suspected melioidosis. Only the first throat swab per illness episode was eligible for inclusion.
The study provides no prescribing or treatment-outcome data. Its discussion notes that targeted treatment is usually prescribed only after laboratory confirmation.
Clinical Best Practices
Throat swabs and enrichment culture remain essential components of the diagnostic workup for melioidosis.
Throat swabs are frequently collected from children and adults unable to expectorate and may provide the only culture-positive specimen.
Greater bacterial burden is associated with AMD-RDT positivity, but the test’s poor sensitivity limits its usefulness on throat swabs.
Related Resources & Content
Diagnostic accuracy of the Active Melioidosis Detect Plus rapid test for detection of Burkholderia pseudomallei in throat swabs — Arjun Chandna, Sena Sao, Joy Silisouk, et al. — International Journal of Infectious Diseases, volume 172, article 109114, 2026; accepted September 9, 2026.
by Arjun Chandna, Sena Sao, Joy Silisouk, Amphone Sengduangphachanh, Thyl Miliya, David A.B. Dance, Sue J. Lee, Koukeo Phommasone, Keang Suy, Tamalee Roberts, Clare L. Ling